3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one inhibits allergic reactions in IgE-mediated RBL-2H3 cells and a passive cutaneous anaphylaxis mouse model

3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one inhibits allergic reactions in IgE-mediated RBL-2H3 cells and a passive cutaneous anaphylaxis mouse model

Abstract Allergic reactions occur when the immune system overreacts to generally harmless substances, leading to both acute and chronic diseases, which can be fatal. Mast cells are critical mediators of allergic reactions as they bind allergens and trigger the release of inflammatory mediators. In t...

Full description

Saved in:
Bibliographic Details
Main Authors: Moonsu Kim, Huiji Kim, Sun Young Moon, Seong-Ah Shin, Minji Kim, Seyeon Choi, Sugeun Gwon, Jun Hyuck Lee, Hyun Ho Park, Chang Sup Lee
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:Applied Biological Chemistry
Subjects:
Allergy
Mast cells
3-Bromo-4-(2-Hydroxyethyl)-7-Methoxy-2H-Chromen-2-One
Anti-Allergic therapeutics
AKT pathway
MAPK pathway
Online Access:https://doi.org/10.1186/s13765-025-00979-x
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Allergic reactions occur when the immune system overreacts to generally harmless substances, leading to both acute and chronic diseases, which can be fatal. Mast cells are critical mediators of allergic reactions as they bind allergens and trigger the release of inflammatory mediators. In this study, we investigated the anti-allergic effects of the coumarin derivative 3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one in rat basophilic leukemia (RBL)-2H3 cells sensitized to dinitrophenyl (DNP)-immunoglobulin E (IgE) and human serum albumin (HSA). Our results demonstrated that 3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one effectively reduces the release of β-hexosaminidase and histamine, inhibiting mast cell degranulation. Additionally, 3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one suppressed the production of allergy-related pro-inflammatory cytokines (IL-4, IL-13, and TNF-α) and inhibited key signaling pathways, including MAPK, AKT, and NF-κB. Furthermore, in a passive cutaneous anaphylaxis (PCA) mouse model, 3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one reduced ear edema and Evans blue infiltration, further confirming its anti-allergic effects. Collectively, these findings suggest that 3-bromo-4-(2-hydroxyethyl)-7-methoxy-2H-chromen-2-one is a promising candidate for the development of anti-allergic therapeutics.
ISSN:2468-0842

Similar Items